The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Novel ex vivo engineered cell therapies to be developed by Vertex Pharma and Arbor Biotechnologies Under this new partnership, Vertex will receive rights to use Arbor’s technology to research ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

This was the stock's second consecutive day of losses.

1 Day VRTX -2.72% DJIA 0.09% S&P 500 -0.19% Health Care/Life Sciences 0.99% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...